PharmaBlock Sciences Nanjing Inc
SZSE:300725
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
24.4
45.55
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
PharmaBlock Sciences Nanjing Inc
Accounts Receivables
PharmaBlock Sciences Nanjing Inc
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
PharmaBlock Sciences Nanjing Inc
SZSE:300725
|
Accounts Receivables
ÂĄ399.7m
|
CAGR 3-Years
43%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
||
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Accounts Receivables
ÂĄ3.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Accounts Receivables
ÂĄ809.6m
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
14%
|
||
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Accounts Receivables
ÂĄ6.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
14%
|
||
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Accounts Receivables
ÂĄ10.1B
|
CAGR 3-Years
21%
|
CAGR 5-Years
36%
|
CAGR 10-Years
28%
|
||
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Accounts Receivables
ÂĄ98.4m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
PharmaBlock Sciences Nanjing Inc
Glance View
PharmaBlock Sciences (Nanjing), Inc. engages in the innovation of chemistry products and services throughout the pharmaceutical research and development process. The company is headquartered in Nanjing, Jiangsu and currently employs 1,735 full-time employees. The company went IPO on 2017-11-10. The firm's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The firm is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.
See Also
What is PharmaBlock Sciences Nanjing Inc's Accounts Receivables?
Accounts Receivables
399.7m
CNY
Based on the financial report for Sep 30, 2024, PharmaBlock Sciences Nanjing Inc's Accounts Receivables amounts to 399.7m CNY.
What is PharmaBlock Sciences Nanjing Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
40%
Over the last year, the Accounts Receivables growth was -11%. The average annual Accounts Receivables growth rates for PharmaBlock Sciences Nanjing Inc have been 43% over the past three years , 40% over the past five years .